Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Apr 23 2010NewsGuard 100/100 Score

Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo® in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.

The oral podium presentation (Abstract #6507) entitled, "Phase II Study of Marqibo in Adult Patients with Refractory or Relapsed Philadelphia Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL)" will be presented in Room E354b at 11:45 a.m. on Monday, June 7.

SOURCE Hana Biosciences, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study shows cannabis as a genotoxic substance with cancer risks
How different types of bread impact cancer risk
Advances in bladder cancer treatments offer hope for curative care
AI-powered tool predicts gene activity in cancer cells from biopsy images
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths
Air pollution linked to head and neck cancer risk
New vaccine shows potential in preventing recurrence of triple-negative breast cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study shows AI can predict prognosis in triple-negative breast cancer